Assessment of atherosclerosis in endometriosis patients: the need to do much more
letter
OA: closed
CC0
⤵ 2 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This paper reviews the current understanding of atherosclerosis in endometriosis patients, highlighting the need for further research in this area.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression 2021
- CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking 2020
- Endometriosis promotes atherosclerosis in a murine model 2022
Cited by (2)
References (5)
- CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking via openalex
- Endometriosis promotes atherosclerosis in a murine model via openalex
- Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression via openalex
- W3201187284 via openalex
- W6801247692 via openalex
Cited by (2)
Source provenance
- europepmc
- last seen: 2026-08-15T06:15:18.721777+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-07-13T06:13:32.449745+00:00
License: CC0
· commercial use OK